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OBJECTIVES This study sought to determine the safety, feasibility and outcome of local delivery of
cytochalasin B at the site of coronary angioplasty.
BACKGROUND Previous failures in the pharmacologic prevention of restenosis may have been related to
inadequate dosing at the angioplasty site as a result of systemic drug administration.
Alternatively, although previous experimental protocols have typically targeted control of
excess tissue growth (intimal hyperplasia), it now appears that overall arterial constriction
(vascular remodeling) is the major contributor to late lumen loss. Cytochalasin B inhibits the
polymerization of actin and has proved to be a potent inhibitor of vascular remodeling in
animal models.
METHODS In this phase I, multicenter, randomized, controlled trial, cytochalasin B (or matching
placebo) was administered to the site of a successful balloon angioplasty using a microporous
local delivery infusion balloon.
RESULTS The rate of drug delivery at a constant infusion pressure varied significantly from patient to
patient (range 1.7 to 20.2 ml/min), perhaps related to a variable constricting effect of the
atherosclerotic plaque on the infusion balloon. The minimal stenosis diameter after the
procedure was slightly better in the active drug group (1.86 6 0.44 vs. 1.49 6 0.63 mm, p ,
0.03), but this difference was not seen at four to six weeks. Although the study was not
powered for clinical outcomes (n 5 43), the combined end point (death, nonfatal infarction
or repeat revascularization) was encountered in 20% of the patients receiving cytochalasin B
and in 38% of the patients receiving placebo. Clinical restenosis occurred in 18% of the
treatment group and 22% of the placebo group. There were no significant differences between
groups in biochemical or electrocardiographic variables.
CONCLUSIONS Cytochalasin B can be safely administered by local delivery after successful coronary
angioplasty and warrants further study of its efficacy in reducing restenosis. (J Am Coll
Cardiol 2000;35:583–91) © 2000 by the American College of Cardiology
Late luminal narrowing is the most common cause of
recurrent angina pectoris in the first few months after a
percutaneous coronary intervention. The pharmacologic
prevention of this process has proved an elusive goal, with
no unequivocally useful agent identified to date. Failure
to achieve adequate drug concentrations has been impli-
cated in the recurring pattern reported in the published
data of favorable animal investigations followed by dis-
appointing human trials (1). The local delivery of a drug
directly to the site of intervention may be more thera-
peutic than systemic administration of the same agent. It
theoretically should provide very high concentrations of
the drug at the target site. In addition, local delivery may
reduce the side effects of otherwise toxic agents. To date,
the local delivery of a number of promising agents has
been studied in animal models, including vascular endo-
thelial growth factor (2), dexamethasone (3), a tyrosine
kinase inhibitor (4), paclitaxel (5), urokinase (6), heparin
(7), r-hirudin (8), thrombin inhibitor (9), colchicine (10)
and c-myc antisense oligomers (11). These agents have
generally targeted the reduction of tissue growth as a
means of suppressing the intimal hyperplastic response.
In contrast, the pharmacologic control of vascular remod-
eling (likely the more important contributor to late
luminal narrowing) has received scant attention. Cy-
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tochalasin B may be useful in inhibiting this detrimental
remodeling process (12–14).
This report documents the results of the first Food and
Drug Administration (FDA)-approved randomized trial
involving local delivery of an experimental agent for the
reduction of coronary restenosis. Cytochalasin B was ad-
ministered by a microporous balloon infusion catheter to the
target lesion immediately after successful balloon angio-
plasty. Biochemical and angiographic analyses were used to
help assess the safety of the procedure.
METHODS
Patient group. Candidates were selected from patients
scheduled to undergo nonemergent percutaneous translu-
minal coronary angioplasty (PTCA), with randomization
occurring immediately after the successful completion of the
angioplasty procedure. Inclusion criteria included: 1) age
.21 and ,80 years; 2) appropriate candidate for balloon
angioplasty, as provided by the American College of Car-
diology/American Heart Association (ACC/AHA) guide-
lines (15); 3) adequate renal and hepatic function; and 4)
ability and willingness to provide written, informed consent.
Patients were excluded if they had any of the following: 1)
target lesion $12 mm in length or ACC/AHA type C
morphology (16); 2) myocardial infarction or thrombolytic
therapy within seven days; 3) unstable angina defined as rest
pain or onset of unstable symptoms within 48 h; 4) previous
target site coronary intervention; 5) target lesion located in
a bypass graft; 6) insulin-dependent diabetes mellitus; 7)
diastolic pressure .100 mm Hg; 8) ejection fraction ,34%;
9) allergy to aspirin or contrast dye; 10) symptomatic carotid
or renal artery stenosis; 11) severe arrhythmias; 12) stroke
within six months; 13) coagulopathy; 14) pregnancy; 15) use
of any other investigational agent within 30 days; 16) use of
a fixed wire balloon catheter, a nonballoon interventional
device or a “bailout” procedure during treatment of the
target lesion; or 17) an angioplasty procedure that was
unsuccessful or was complicated by a major dissection (class
C through F according to the National Heart, Lung, and
Blood Institute [NHLBI]) (17). The study received full
approval from each center’s Institutional Review Board.
Coronary angioplasty and quantitative angiography.
Balloon angioplasty was performed in accordance with
standard practice (15) and included the use of periproce-
dural aspirin and heparin. The choice of additional medi-
cations, balloon catheters and inflation protocol was left to
the discretion of the investigator. Angiographic images were
obtained before angioplasty, after angioplasty and after local
delivery of the study drug in at least two views after
intracoronary injection of 100 to 200 mg of nitroglycerin.
Follow-up angiography was performed four to six weeks
after randomization in 17 patients, including all those in the
highest dose treatment group. This period was selected to
coincide with animal studies that demonstrated effective
inhibition of remodeling four weeks after cytochalasin B
administration (13,14). Consistent angiographic views were
maintained throughout the procedure and during follow-up
angiography.
All procedural and follow-up cineangiograms were for-
warded to the Washington Hospital Center’s Angiographic
Core Laboratory for analysis by observers who had no
knowledge of treatment strategy. Standard morphologic
criteria were used to characterize baseline lesion complexity
(18) and to identify the occurrence of angiographic compli-
cations (19). Lesion length was determined by the
“shoulder-to-shoulder” axial obstruction extent. Cine
frames were selected from the two “sharpest and most
severe” projections of the stenosis before and after the initial
procedure and at late follow-up; sequential cine frames were
matched for their position within the cardiac cycle. Quan-
titative angiographic analysis was performed using the
CAAS algorithm (20). Using the contrast-filled injection
catheter for image calibration, the minimal lumen diameter
(MLD) and mean reference diameter (RD) were used to
calculate the percent diameter stenosis ([1 2 MLD/RD] 3
100). An MLD of 0.0 was imputed in the presence of a total
occlusion at baseline or follow-up. Binary restenosis was
defined as .50% follow-up diameter stenosis.
Local drug delivery. Immediately after balloon angio-
plasty, the dilating balloon catheter was exchanged for the
drug delivery catheter. This balloon catheter (Microporous
Infusion Catheter, Cordis, Miami, Florida) was constructed
from a porous inner balloon with 64 pores of 25 mm in
diameter, which provided most of the balloon’s strength.
This was surrounded by a microporous membrane contain-
ing a high density of 0.8-mm pores that permitted con-
trolled delivery of the study drug without jetting of fluid into
the surrounding arterial wall (21). Each drug delivery
balloon was 20 mm in length, and its diameter was
individually selected to match the nominal diameter of the
dilating balloon. The drug delivery balloon was centered in
the dilated lesion and inflated between 4 and 5 atm for a
total of 90 s. Patients unable to tolerate 90 continuous
seconds of interrupted coronary blood flow (14% of patients
overall) received two or more inflations for a total inflation
time of 90 s. Based on in vitro and animal data, it was
Abbreviations and Acronyms
AHA 5 American Heart Association
ACC 5 American College of Cardiology
CAAS 5 coronary angiography analysis system
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NHLBI 5 National Heart, Lung and Blood Institute
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anticipated that this inflation protocol would deliver be-
tween 9 and 24 ml of study drug (at a flow rate of 6 to
18 ml/min) to the treatment site. However, the actual total
dose of the study drug delivered differed somewhat from
patient to patient, as the drug was infused through the
catheter at a constant infusion pressure, not infusion rate.
No upper limit was set for the volume of drug infused.
Dosing regimen. This phase I study was designed using a
randomized, double-blind, placebo-controlled, dose-
escalating protocol. The first 10 patients received cytocha-
lasin B (Biostent, NeoRx Corporation, Seattle, Washing-
ton) at a concentration of 0.1 mg/ml (vs. placebo in a 4:1
ratio of active drug to placebo); the second 10 patients
received a concentration of 0.5 mg/ml (4:1 active drug to
placebo); the third 10 patients received a concentration of
1.5 mg/ml (4:1 active drug to placebo); and the final group
of 13 patients received a concentration of 8.0 mg/ml (1:1
active drug to placebo). The dose of 8.0 mg/ml represents
the maximal solubility of the study drug in aqueous solution.
Assessment of safety. Blood and urine tests were obtained
at baseline and at 24 h, seven days and 24 weeks after study
drug administration and included measures of renal and
hepatic function, electrolytes, lipid metabolism, hemato-
logic variables and markers of myocardial injury. Electro-
cardiograms and vital signs were also obtained at these same
intervals. Clinical safety assessments were performed in
person or by telephone at 24 h, seven days and four-week
intervals thereafter until completion of the study at six
months.
Data analyses. Although this trial was designed as a phase
I study, the sample size provided adequate statistical power
(alpha 5 0.05 and beta 5 0.10) to detect a clinically
important difference (0.5 mm) in net gain in MLD between
the two treatment groups. Continuous and categoric data
were analyzed using paired and the unpaired t test and the
Fischer exact test. The change in MLD was analyzed using
analysis of covariance, with the immediate post-PTCA
MLD taken as a covariate. The transition in aneurysm,
dissection or Thrombolysis in Myocardial Infarction trial
(TIMI) status from pre-PTCA to post drug infusion and to
four- to six-week follow-up was computed by the Stuart
Maxwell test for each treatment group. Multiple linear
regression analysis was used to study variables that poten-
tially influenced the drug delivery rate.
RESULTS
Patient demographic data. A total of 43 patients were
enrolled in this study, and each received the study drug (or
placebo) by local catheter delivery as described earlier. These
43 patients were divided into two groups, based on whether
they received cytochalasin B (n 5 30) or placebo (n 5 13).
The drug-treated group was further stratified into four
subgroups, based on the concentration of cytochalasin B
received—0.1 mg/ml (n 5 8), 0.5 mg/ml (n 5 8), 1.5 mg/ml
(n 5 8) and 8.0 mg/ml (n 5 6). Table 1 provides baseline
demographic and clinical data for each main group. Impor-
tantly, there were no statistically significant differences
between the drug group and the placebo group.
Drug delivery rate. Figure 1 demonstrates the wide vari-
ability from patient to patient in flow rates provided by the
drug delivery catheter, despite a consistent fluid-driving
pressure of 4 to 5 atm. This is in contrast to the relatively
low variability encountered using the same catheter in vitro
or in a nondiseased intact porcine coronary model. One
Table 1. Baseline Characteristics
Cytochalasin B Group
(n 5 30)
Placebo Group
(n 5 13)
Clinical variables
Age (yrs) 60 6 11 57 6 12
Male gender (%) 83% 77%
Weight (kg) 93 6 15 89 6 18
Historic variables (%)
Previous MI 47% 39%
Hypertension 60% 54%
Smoking 57% 77%
Hyperlipidemia 20% 46%
Hemodynamic/angiographic variables
Heart rate (min21) 68 6 12 66 6 12
Systolic pressure (mm Hg) 137 6 22 132 6 11
Ejection fraction (%) 61 6 12% 58 6 15%
No. of vessels with CAD (%)
One 50% 31%
Two 40% 62%
Three 10% 8%
Data are presented as the mean value 6 SD or percentage of patients. All differences are statistically nonsignificant.
CAD 5 coronary artery disease; MI 5 myocardial infarction.
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explanation for this disparity involves a variable-constricting
effect of the human atherosclerotic plaque on the inflated
balloon, thereby impeding the delivery of fluid across the
porous membrane. The role of factors that might potentially
contribute to this wide variability was explored using both
simple and multiple linear regression analysis (Table 2). We
studied the relation of the diameter of the inflated drug
delivery balloon to five measurements of coronary size: 1)
the lumen diameter of the adjacent coronary artery free of
obvious disease (RD); 2) the smallest lumen diameter of the
lesion before intervention (MLD before PTCA); 3) the
smallest lumen diameter of the lesion after completion of
PTCA but before insertion of the drug delivery catheter
(MLD after PTCA); 4) the nominal diameter of the PTCA
balloon used (nominal balloon); and 5) the predicted max-
imal diameter of the PTCA balloon based on the maximal
inflation pressure used and the manufacturer’s balloon
compliance data (predicted balloon).
The MLD after PTCA showed the strongest univariate
correlation to the drug delivery rate, although the correla-
tion coefficient was small (r 5 0.068) and the relation was
not statistically significant (p 5 0.67). In an attempt to
improve the predictive power, a multivariate model was
created (Table 2). No important improvement was realized,
however, because the model was only able to account for 1%
of the wide variance in delivery rate observed during the
study (multiple r 5 0.103). Figure 2 details the relation
between the drug delivery rate and the single best predictor—
MLD after PTCA. The slight downward slope of the multi-
variate regression line suggests that the rate is lower for drug
delivery balloons that are “oversized” relative to the dimensions
of the residual stenosis, but this effect is overshadowed by the
wide scatter of data points and the marked disparity between
observed and predicted values shown on the graph.
Quantitative coronary angiographic measurements.
Blinded quantitative angiographic measurements are shown
in Table 3. Baseline values of MLD, RD and percent
diameter stenosis were similar between the groups. How-
ever, immediately after balloon angioplasty and local drug
delivery, the stenosis lumen was larger in patients treated
with cytochalasin B than in those given placebo (mean
MLD 1.86 6 0.44 vs. 1.49 6 0.63 mm), a difference of
borderline statistical significance (p 5 0.03). Both groups
showed a modest reduction in MLD from immediately
before to immediately after drug infusion (20.16 6 0.29 vs.
20.24 6 0.76 mm, p 5 NS).
Figure 1. Delivery rate to angioplasty site during infusion of
cytochalasin B/placebo, shown individually for each patient.
Figure 2. Scatter plot demonstrating the relation between the drug
delivery rate and the relative size of the infusion balloon, expressed
as a ratio of its diameter to the MLD of the stenosis after balloon
angioplasty. Solid circles represent the observed delivery rates; the
line represents the results of multiple linear regression; and the
open circles represent the predicted rates based on the multivariate
model. Note the low correlation coefficient (r 5 0.068) and the
poor correspondence between observed and predicted values.
Table 2. Predictors of Drug Infusion Rate
Univariate Analysis Multivariate Analysis
r p Value r p Value
MLD after PTCA 0.068 0.67 20.61 0.66
Reference diameter 0.053 0.74 2.53 0.76
Nominal PTCA balloon diameter 0.044 0.78 27.36 0.74
Predicted PTCA balloon diameter 0.015 0.92 20.78 0.97
MLD before PTCA 0.013 0.93 20.06 0.92
MLD 5 minimal lumen diameter; nominal PTCA balloon diameter 5 diameter at nominal inflation pressure as provided by
each manufacturer; predicted PTCA balloon diameter 5 diameter at the maximal inflation pressure used in each patient based
on balloon compliance data provided by each manufacturer; PTCA 5 percutaneous transluminal coronary angioplasty.
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A total of 17 patients received protocol-specified angiog-
raphy at four to six weeks. There was a nonsignificant trend
toward less change (smaller improvement) in MLD in the
drug group as compared with the placebo group (0.09 6
0.31 vs. 0.42 6 0.46 mm, p 5 NS). The overall net gain in
MLD from pre-PTCA to the four- to six-week angiogram
was 0.92 6 0.40 and 1.14 6 0.47 mm, respectively (p 5
NS).
Angiographic morphology. Blinded analysis of the coro-
nary angiograms by the core laboratory revealed luminal
irregularities classified as dissections in 36% of patients
immediately after balloon angioplasty. As shown in Figure
3, this proportion increased to 48% immediately after local
drug/placebo delivery (p 5 NS), with six angiograms
revealing the creation of a new dissection, four demonstrat-
ing worsening of an established dissection and one showing
resolution of an established dissection. The frequency of
angiographic dissection after local drug delivery was statis-
tically similar (45% vs. 54%) between patients who received
cytochalasin B infusion at any dose (drug group) and those
who received placebo infusion (placebo group). Analysis of
the 17 patients (40% of enrollees) with routine follow-up
angiograms obtained at four to six weeks demonstrated
spontaneous healing and resolution of dissections in all but
one patient.
The presence of a new or worsened dissection after drug
delivery could not be predicted by the drug/placebo infusion
rate, with a mean rate of 9.6 ml/min for patients with a new
or worsened dissection versus 11.3 ml/min for those without
a dissection (p 5 0.28). Similarly, the relative size of the
drug delivery balloon could not be shown, statistically, to
influence the likelihood of developing a dissection. The
mean ratio of drug delivery balloon to post-PTCA stenosis
lumen diameter (MLD) was 1.95 for patients with a new or
worsened dissection and 1.75 for patients without a dissec-
tion (p 5 0.35), and the mean ratio of balloon to reference
segment diameter was 1.07 for patients with a new or
worsened dissection and 1.02 for patients without a dissec-
tion (p 5 0.25).
On routine four- to six-week angiography, 3 (18%) of 17
patients showed the appearance of a small (mean diameter
2.6 mm) aneurysmal outpouching near the site of the initial
target stenosis that was not observed before balloon angio-
plasty, after balloon angioplasty or after drug delivery (Fig.
4). Two of these patients had received cytochalasin B and
one placebo. Intravascular ultrasound evaluation of one of
these diverticula revealed that it was confined to the ath-
erosclerotic plaque and adjacent intima, excluding a true
anatomic arterial aneurysm.
Biochemical and ECG variables. Analyses of blood and
urine samples were performed at four different points during
the study. There were no significant changes in renal
function indexes, hepatic function indexes, hematologic
variables or coagulation variables at any time during the
treatment or follow-up period. Similarly, there were no
apparent short-term or long-term changes observed in the
ECG related to the delivery of cytochalasin B.
Clinical outcomes. The combined study end point (death,
nonfatal myocardial infarction and/or repeat coronary revas-
cularization) was encountered in 11 patients over the six-
month follow-up period (Table 4), occurring in 38% of the
placebo group and 20% of the drug group (p 5 NS). Two
patients died. One patient in the placebo group experienced
threatened abrupt closure in the laboratory, which was
Figure 3. The frequency and severity of angiographic dissections
observed immediately after balloon angioplasty and immediately
after local drug delivery. The letters A through F denote progres-
sive grades of severity, with the corresponding boxes representing
the number of patients with dissections in each grade. The width
of each interconnecting line is proportional to the number of
patients involved. One patient was excluded from this blinded
analysis because his cineangiographic film was not available.
Table 3. Quantitative Coronary Angiographic Measurements
Drug
Group
Placebo
Group
At baseline
MLD at baseline (mm) 1.05 6 0.31 1.01 6 0.39
Reference diameter (mm) 2.91 6 0.40 2.86 6 0.51
Percent diameter stenosis 64 6 11 65 6 11
After initial procedure
MLD after infusion (mm) 1.86 6 0.44 1.49 6 0.63*
DMLD with infusion (mm) 20.16 6 0.29 20.24 6 0.76
Acute gain (mm) 0.78 6 0.53 0.48 6 0.74
After four- to six-week
angiogram
Delayed gain (mm) 0.09 6 0.31 0.42 6 0.46
Net gain (mm) 0.92 6 0.40 1.14 6 0.47
*p 5 0.03. Data are presented as the mean value 6 SD.
Acute gain 5 difference between MLD after infusion and before PTCA; delayed
gain 5 difference between MLD at four to six weeks and MLD after infusion;
MLD 5 minimal lumen diameter of the stenosis; DMLD with infusion 5 change in
MLD after infusion and MLD after percutaneous transluminal coronary angioplasty
(PTCA); net gain 5 difference between MLD at four to six weeks and MLD before
PTCA.
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successfully treated with further PTCA therapy. Eight
hours later, the patient had fatal ventricular fibrillation. The
other fatality occurred in a patient in the 0.5-mg/ml cy-
tochalasin B drug group. An intracoronary stent was placed
after local drug delivery owing to a suboptimal angiographic
result. Ten days later, angiographically documented sub-
acute stent thrombosis occurred in the setting of binge
drinking and noncompliance with all prescribed medica-
tions. The patient died six days later from complications
arising from this myocardial infarction.
One patient experienced symptomatic restenosis at four
to six weeks, as documented on the study-mandated coro-
nary angiogram. In addition, late (.6 weeks) angiography
was performed for clinical indications in eight patients who
had recurrent chest pain. Restenosis (diameter stenosis
.50%) was observed in six patients, all of whom went on to
receive repeat target lesion revascularization by either oper-
ation or percutaneous intervention. For the purpose of
computing the restenosis rate, patients were included if they
had restenosis or if they received a full six months of clinical
follow-up without angiographic restenosis. The one patient
who received emergent coronary artery bypass graft surgery
for failed PTCA during his initial procedure was excluded,
as restenosis of the target lesion, if it occurred, would likely
be clinically unapparent. When patients were grouped
according to assigned treatment, the angiographically con-
firmed restenosis rate was 18% for the treatment group and
22% for the placebo group.
DISCUSSION
Vascular remodeling and cytochalasin B. Renarrowing of
the coronary lumen after balloon angioplasty can result from
a combination of encroachment by new tissue growth
(neointimal hyperplasia) or constriction of the entire cross
section of the artery (vascular remodeling) (22). Because
67% to 83% of late loss in the initial gain afforded by balloon
angioplasty is due to this remodeling process (23–25),
previous pharmacologic efforts designed to blunt the hyper-
plastic component of restenosis might fail to eliminate
clinically important renarrowing, even if they were success-
ful. A strategy that includes targeting the cellular mecha-
nisms involved in remodeling may ultimately be required for
a meaningful clinical response.
Cytochalasin B is a member of a family of fungal
metabolites first identified in 1967 and grouped according
to their ability to cause polyploidy in dividing cells (26).
This property arises from the disruption of cytoskeletal
function, an effect that also leads to inhibition of platelet
aggregation, clot retraction, migration and phagocytosis.
Specifically, cytochalasin B inhibits the polymerization of
actin into microfilaments by blocking the terminal addition
of new actin monomers (27). During balloon angioplasty,
vascular smooth muscle cells undergo microfilament de-
polymerization as a consequence of direct trauma. As a
result, these cells undergo a phenotypic change from a
contractile to a secretory/migratory phenotype. Cytochala-
sin B delivered to the arterial wall near the time of
PTCA-induced depolymerization leads to capping of actin
filaments, thereby preventing the normal process of repoly-
merization that occurs over the ensuing weeks. Preclinical
data suggest that delaying this natural repolymerization
results in matrix secretion while the artery is in its maximally
dilated state, thereby increasing arterial wall stiffness and
reducing remodeling. The ability to decrease restenosis with
cytochalasin B through sustained dilation as opposed to
inhibition of neointimal thickening has been shown in
porcine femoral and coronary balloon injury models (13,14).
Local drug delivery procedure. The drug/placebo solution
was delivered successfully in every patient, with the target
infusion rate of 6 to 16 ml/min obtained in 79% of the study
group. Nevertheless, Figure 1 reveals a wide variability in
the drug delivery rate, well in excess of the narrow range of
flow rates recorded when the same delivery system was
studied in vitro or in a nonatherosclerotic animal artery. In
Figure 4. Example of an asymptomatic angiographic “aneurysm”
observed on the four- to six-week follow-up (f/u) study that was
not present either before balloon angioplasty (pre) or immediately
after local drug/placebo delivery (post). The thin arrows denote
the site of the stenosis; the thick arrow indicates the aneurysm.
Table 4. Primary End Point
Drug Group Placebo Group
Death 1 (3%) 1 (8%)
Nonfatal MI 0 (0%) 1 (8%)
Revascularization 5 (17%) 3 (23%)
Total 6 (20%) 5 (38%)
Data are presented as the number (%) of patients.
MI 5 myocardial infarction.
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this trial, the nominal diameter of the drug delivery balloon
was selected to match the nominal diameter of the PTCA
balloon. However, it is possible that this method of balloon
sizing for ideal “fit” and drug delivery is suboptimal, given
the complex morphology, variable radial compliance and
unpredictable elastic recoil present in human atherosclerotic
lesions. Attempts to explain this variability were not partic-
ularly fruitful, but did raise the possibility that selection of
the ideal drug delivery balloon diameter might be improved
by relating it to the MLD of the stenosis after PTCA, a
measurement now rapidly available in many catheterization
laboratories through in-laboratory quantitative coronary
angiography.
The wide variability in flow rates encountered is not
necessarily deleterious. Drug penetrance into the lesion is
most directly related to maintenance of a steady head of
driving pressure, and is therefore more pressure-dependent
than flow-dependent. Numerous drug investigations into
the techniques of local drug delivery have verified that only
a small fraction of infused agent (,2.5%) is actually depos-
ited within the arterial wall, with the remainder either
dispersed in the periadventitial space or myocardium or
washed downstream into the systemic circulation (28).
Angiographic analyses. Quantitative coronary angiogra-
phy was performed at four time points—before PTCA,
after PTCA but before drug delivery, after drug delivery and
(in selected patients) at four to six weeks after the procedure.
One unexpected finding in this trial was an apparent
improvement in early results (greater MLD) in patients
treated with higher doses of cytochalasin B (p 5 0.03). The
postulated mechanism for restenosis reduction by the study
drug implies a more delayed effect. However, cytochalasins
possess additional biologic activities, such as interference
with platelet function (29), that might contribute to this
early phenomenon.
Both drug and placebo groups experienced a modest
decrease in MLD after the local infusion. Whether this was
related to the local delivery procedure per se or to the
well-described phenomenon of transient luminal constric-
tion immediately after PTCA (30) cannot be ascertained
from this trial. By four to six weeks, the MLD had
improved in both groups, consistent with recent data
describing the typical time course of lumen diameter
changes after balloon angioplasty (31). A nonsignificant
trend toward a less marked change in mean MLD was
found with the cytochalasin B–treated group. This would be
consistent with the hypothesis of drug-induced inhibition of
remodeling, perhaps blocking short-term favorable as well
as long-term unfavorable changes in MLD.
Minor angiographic dissections are commonly seen after
successful balloon angioplasty. Indeed, pathologic studies
have shown that intimal flaps are a regular feature of balloon
dilation (32), with some investigators reporting a lower
restenosis rate in treated lesions showing angiographic
evidence of a local dissection (33). In contrast, severe
dissections may lead to abrupt vessel closure and a poor
clinical result. In this study, careful analysis at the core
angiography laboratory revealed a dissection frequency after
PTCA of 38%, a value consistent with other core laboratory
readings (34,35). The apparent further increase in the
frequency and severity of dissections after local infusion is
worthy of note. All but four of the dissections observed after
infusion were classified as nonsevere (grades A through C);
all of the more severe dissections were present before drug
infusion; and all but one dissection resolved spontaneously
in four to six weeks in patients receiving follow-up angiog-
raphy. Whether the local drug delivery process itself can
produce arterial injury has been previously explored in
animal models, with conflicting results reported to date.
Some investigators have demonstrated significant arterial
injury after infusion into atherosclerotic and nonatheroscle-
rotic arteries, with an injury pattern suggestive of jet-related
dissections (36,37). In contrast, other investigators have
found no increased injury (38,39). It is possible that the
delivery of solute into the arterial wall results in an increase
of fluid in the extracellular space and uncoupling of cells,
resulting in propagation of dissection. Given this uncer-
tainty, a careful evaluation of this phenomenon in future
local drug delivery trials is warranted. Additional planned
clinical studies of cytochalasin B will use a different style of
drug delivery catheter; this may help determine whether it is
the design of the drug delivery system per se or the infusion
process itself that produces these altered angiographic find-
ings (38).
Angiographic “aneurysms” are uncommon after balloon
angioplasty (40). The presence of three such aneurysms in
this small cohort raises the possibility that they were related
to the local drug delivery procedure. Alternatively, the true
prevalence of angiographic aneurysms after routine PTCA
could be underappreciated, as routine follow-up angiogra-
phy is rarely performed in this four- to six-week time frame.
Anecdotal intravascular ultrasound data from this study
suggest that the observed diverticula are not true arterial
aneurysms (pseudoaneurysms), as their extent of involve-
ment appeared to be limited to the atherosclerotic plaque
and nearby intima. Except for one instance of early resten-
osis, all three patients experienced a benign course during
six months of follow-up.
Clinical outcomes and future directions. This study was
neither designed nor powered to reliably detect differences
in clinical outcomes. The 47% reduction in the primary
end point and the 19% reduction in clinical restenosis
observed with cytochalasin B should not be interpreted as
evidence of drug efficacy, given the wide confidence limits
afforded by the small patient group. Nevertheless, the results
obtained are useful in establishing the safety of the tech-
nique. They also provide the framework for future clinical
trials with active local drug delivery, in general, and with
therapy using cytochalasin B, in particular. A large-scale
589JACC Vol. 35, No. 3, 2000 Lehmann et al.
March 1, 2000:583–91 Local Delivery of Cytochalasin B
study will be required in the future to accurately assess the
efficacy.
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